'Substantial benefit' (≥ 50% reduction in pain or PGIC very much improved) · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Withdrawals due to adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Lack of efficacy withdrawal · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Serious adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Death · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
Naloxone + oxycodone prolonged release tablets showed no clear difference in symptoms of opioid withdrawalfin the medium termb compared with oxycodone prolonged‐released tablets (low certainty).
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).
1 finding from 1 review
Adverse events · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
Naloxone + oxycodone prolonged release tablets showed no clear difference in adverse events compared with oxycodone prolonged‐released tablets (low certainty).
1 finding from 1 review